Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis

Company Overview

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

Key Stats

• Today's Range: $0.33 to $0.33
• 50-Day Range: $0.27 to $0.78
• 52-Week Range: $0.12 to $1.13
• Volume: N/A
• Average Volume: 702 shs
• Market Capitalization: $2.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CPMV Stock Analysis - Frequently Asked Questions

How have CPMV shares performed this year?

Mosaic ImmunoEngineering's stock was trading at $0.7012 at the beginning of 2025. Since then, CPMV stock has decreased by 53.1% and is now trading at $0.3286.
View the best growth stocks for 2025 here.

How were Mosaic ImmunoEngineering's earnings last quarter?

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) released its quarterly earnings results on Tuesday, May, 20th. The company reported ($0.03) earnings per share (EPS) for the quarter.

How do I buy shares of Mosaic ImmunoEngineering?

Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mosaic ImmunoEngineering own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Applied Genetic Technologies (AGTC), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and

Company Calendar

• Last Earnings: 5/20/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CPMV
• CIK: 836564
• Web: www.ptsc.com
• Phone: (657) 208-0890
• Fax: 760-547-2705
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$920 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,117.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.94) per share
• Price / Book: -0.35

Miscellaneous

• Outstanding Shares: 7,240,000
• Free Float: 1,377,000
• Market Cap: $2.38 million
• Optionable: Not Optionable
• Beta: -0.13